US Pharmaceuticals Secures Growth Funding from 1315 Capital
### USpharma Secures Significant Investment to Expand Health Solutions Offerings
USpharma, a renowned pharmaceutical development and manufacturing company, has recently secured a substantial growth equity investment from 1315 Capital, a healthcare-focused growth equity firm based in Philadelphia. This investment is set to accelerate the development and commercialization of USpharma's pipeline, scaling its operations to meet the growing market demand [1][2][4].
The investment will enable USpharma to continue its innovative work, commercializing several novel delivery platforms, including next-generation soft chewable dosage forms. These platforms are designed to improve patient access and adherence by offering formulations that align with consumer preferences and lifestyles [1][2].
In addition to its innovative delivery systems, USpharma leverages advanced and patented formulation technologies to develop and manufacture products across multiple pharmaceutical and supplement markets [1][2]. The company's primary facility, a 150,000-square-foot GMP-compliant facility located in the United States, will be scaled up to meet the increasing market demand.
With the support of 1315 Capital, USpharma plans to expand its commercial reach, providing compelling product formulations in numerous large and growing healthcare markets. This strategic partnership comes at a pivotal stage of growth for USpharma, as it positions the company to navigate the challenges of the current market trends, which are characterized by cautious deal-making and regulatory uncertainty [3].
Matthew Reber, a Partner at 1315 Capital, expressed his pride in partnering with USpharma as they expand their commercial reach. Manesh Dixit, Ph.D., the Chief Executive Officer of USpharma, expressed his gratitude for the investment, stating that it will help USpharma advance its mission to deliver science-backed, high-quality health solutions.
References: [1] PR Newswire. (2022, April 27). 1315 Capital Makes Significant Growth Equity Investment in USpharma. Retrieved from https://www.prnewswire.com/news-releases/1315-capital-makes-significant-growth-equity-investment-in-uspharma-301558303.html [2] Business Wire. (2022, April 27). 1315 Capital Announces Growth Equity Investment in USpharma. Retrieved from https://www.businesswire.com/news/home/20220427005366/en/1315-Capital-Announces-Growth-Equity-Investment-in-USpharma [3] Fierce Pharma. (2022, April 27). USpharma lands $100M in funding to grow its soft chewable drug business. Retrieved from https://www.fiercepharma.com/pharma/uspharma-lands-100m-funding-to-grow-its-soft-chewable-drug-business
- The growth equity investment from 1315 Capital will also facilitate USpharma's exploration into the health-and-wellness sector, introducing science-backed supplements that cater to fitness-and-exercise and nutrition needs.
- With the expanding product portfolio, USpharma aims to leverage advanced science to develop proven fitness supplements, addressing the growing market demand for nutritional support during exercise and fitness routines.
- The investment in USpharma is not only focused on pharmaceuticals but also on the development of nutrition-based solutions, consolidating its position as a pioneer in the health-and-wellness industry while maintaining its focus on science-backed, high-quality health solutions.
